{"id":"ustekinumab-sc","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ustekinumab binds to the p40 subunit shared by both IL-12 and IL-23, preventing these cytokines from activating T cells and other immune cells that drive chronic inflammation. By inhibiting these pathways, it reduces pathogenic Th1 and Th17 cell responses implicated in autoimmune and inflammatory diseases. This dual IL-12/IL-23 inhibition provides broad immunomodulatory effects across multiple inflammatory conditions.","oneSentence":"Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of immune-mediated inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:44.405Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT05092269","phase":"PHASE3","title":"A Long-term Extension Study of Ustekinumab in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-18","conditions":"Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic","enrollment":159},{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT07310095","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)","status":"RECRUITING","sponsor":"Xian-Janssen Pharmaceutical Ltd.","startDate":"2025-12-30","conditions":"Crohn Disease","enrollment":78},{"nctId":"NCT03466411","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-13","conditions":"Crohn's Disease","enrollment":1409},{"nctId":"NCT05083182","phase":"PHASE3","title":"A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-08-30","conditions":"Arthritis, Juvenile","enrollment":50},{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease","enrollment":100},{"nctId":"NCT05387031","phase":"","title":"Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-01","conditions":"Crohn Disease, Stricture; Bowel, Intestinal Stricture","enrollment":239},{"nctId":"NCT04572815","phase":"PHASE2","title":"Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-05-14","conditions":"Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm","enrollment":116},{"nctId":"NCT07303686","phase":"PHASE4","title":"De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-10-08","conditions":"Crohn Disease (CD), Ulcerative Colitis (UC)","enrollment":115},{"nctId":"NCT03167437","phase":"PHASE1, PHASE2","title":"An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-10-30","conditions":"Crohn's Disease","enrollment":35},{"nctId":"NCT04232553","phase":"PHASE3","title":"A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-06-22","conditions":"Crohn's Disease","enrollment":996},{"nctId":"NCT07263464","phase":"","title":"The Association Between TNFSF4 Polymorphism and CD","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2018-01-01","conditions":"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Polymorphism, Single Nucleotide, Ustekinumab","enrollment":818},{"nctId":"NCT04673357","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-06","conditions":"Crohn Disease","enrollment":101},{"nctId":"NCT03651518","phase":"PHASE2","title":"Personalized Therapies in Inflammatory Complex Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-20","conditions":"Inflammatory Disease, Autoimmune Diseases","enrollment":32},{"nctId":"NCT05029921","phase":"PHASE4","title":"A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-12-10","conditions":"Crohn Disease","enrollment":182},{"nctId":"NCT07149467","phase":"PHASE3","title":"Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-09-10","conditions":"Crohn's Disease Aggravated, Crohn's Disease in Remission","enrollment":454},{"nctId":"NCT03358706","phase":"PHASE1","title":"A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-02","conditions":"Crohn Disease, Ulcerative Colitis","enrollment":28},{"nctId":"NCT04524611","phase":"PHASE3","title":"Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-09-30","conditions":"Crohn's Disease (CD)","enrollment":527},{"nctId":"NCT04630028","phase":"PHASE3","title":"A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-17","conditions":"Colitis, Ulcerative","enrollment":112},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT03981744","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-26","conditions":"Polymyositis, Dermatomyositis","enrollment":51},{"nctId":"NCT03782376","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2018-12-20","conditions":"Crohn Disease","enrollment":215},{"nctId":"NCT03517722","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-16","conditions":"Lupus Erythematosus, Systemic","enrollment":516},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":"Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT02877134","phase":"PHASE2","title":"Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-25","conditions":"Crohn Disease","enrollment":388},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":"Axial Spondyloarthritis","enrollment":347},{"nctId":"NCT04882072","phase":"PHASE3","title":"A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)","status":"TERMINATED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-09-15","conditions":"Takayasu Arteritis","enrollment":14},{"nctId":"NCT02407236","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-10","conditions":"Colitis, Ulcerative, Inflammatory Bowel Diseases","enrollment":961},{"nctId":"NCT03107793","phase":"PHASE3","title":"Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2017-04-19","conditions":"Crohn Disease","enrollment":500},{"nctId":"NCT04816513","phase":"PHASE1","title":"A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-14","conditions":"Healthy","enrollment":300},{"nctId":"NCT02968108","phase":"PHASE1","title":"A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-01-18","conditions":"Crohn Disease","enrollment":45},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT06935942","phase":"","title":"The Associations of Plasminogen Activator Inhibitor-1 Gene Polymorphisms With Crohn's Disease in Chinese Patients","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":906},{"nctId":"NCT06935929","phase":"","title":"A Study on the Associations Between Microribonucleic Acid Gene Polymorphisms and Crohn's Disease","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Wenzhou Medical University","startDate":"2020-01-01","conditions":"Crohn Disease","enrollment":839},{"nctId":"NCT05299931","phase":"PHASE3","title":"An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2021-09-10","conditions":"Crohn Disease","enrollment":108},{"nctId":"NCT01369355","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-09-13","conditions":"Crohn's Disease, Colitis, IBD","enrollment":1282},{"nctId":"NCT04030533","phase":"PHASE1","title":"Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-29","conditions":"Healthy","enrollment":60},{"nctId":"NCT04060888","phase":"PHASE3","title":"A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-14","conditions":"Lupus Erythematosus, Systemic","enrollment":""},{"nctId":"NCT03362736","phase":"","title":"An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT06786507","phase":"","title":"A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Helwan University","startDate":"2025-05-15","conditions":"Ulcerative Colitis (UC)","enrollment":100},{"nctId":"NCT03926130","phase":"PHASE3","title":"A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-07-23","conditions":"Crohn's Disease","enrollment":1158},{"nctId":"NCT04607980","phase":"PHASE3","title":"A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-11-11","conditions":"Plaque Psoriasis","enrollment":563},{"nctId":"NCT04089345","phase":"PHASE3","title":"Stelara fOr ChRonic AntibioTic rEfractory pouchitiS","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-06-15","conditions":"Pouchitis","enrollment":20},{"nctId":"NCT05169593","phase":"PHASE4","title":"Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-09-08","conditions":"Crohn Disease","enrollment":292},{"nctId":"NCT05890118","phase":"PHASE1","title":"Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule","status":"COMPLETED","sponsor":"RANI Therapeutics","startDate":"2023-08-30","conditions":"Healthy Volunteers","enrollment":55},{"nctId":"NCT04761627","phase":"PHASE3","title":"A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-03-24","conditions":"Psoriasis","enrollment":494},{"nctId":"NCT04728360","phase":"PHASE3","title":"Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2021-07-06","conditions":"Plaque Psoriasis","enrollment":556},{"nctId":"NCT04595409","phase":"PHASE3","title":"A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Bioeq GmbH","startDate":"2020-11-09","conditions":"Plaque Psoriasis","enrollment":392},{"nctId":"NCT04930042","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2021-06-03","conditions":"Psoriasis","enrollment":581},{"nctId":"NCT04744363","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2021-05-25","conditions":"Psoriasis","enrollment":294},{"nctId":"NCT04843631","phase":"PHASE1","title":"Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults","status":"COMPLETED","sponsor":"BioFactura Australia Pty Ltd.","startDate":"2021-04-01","conditions":"Psoriasis","enrollment":216},{"nctId":"NCT02684357","phase":"PHASE3","title":"BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":577},{"nctId":"NCT02684370","phase":"PHASE3","title":"BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02","conditions":"Psoriasis","enrollment":560},{"nctId":"NCT02561806","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-10","conditions":"Plaque Psoriasis","enrollment":302},{"nctId":"NCT02349061","phase":"PHASE2","title":"A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-15","conditions":"Lupus Erythematosus, Systemic","enrollment":102},{"nctId":"NCT01708603","phase":"PHASE3","title":"P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-08","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":1831},{"nctId":"NCT01708629","phase":"PHASE3","title":"Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2012-09","conditions":"Plaque Psoriasis","enrollment":1881},{"nctId":"NCT02407223","phase":"PHASE3","title":"An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-13","conditions":"Nonradiographic Axial Spondylitis, Ankylosing","enrollment":356},{"nctId":"NCT02117765","phase":"PHASE1, PHASE2","title":"Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-03","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT01945086","phase":"PHASE2","title":"A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2013-09","conditions":"Dermatitis, Atopic","enrollment":79},{"nctId":"NCT01009086","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-12","conditions":"Arthritis, Psoriatic","enrollment":615},{"nctId":"NCT01090427","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Psoriasis","enrollment":110},{"nctId":"NCT01059773","phase":"PHASE4","title":"A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2009-10","conditions":"Psoriasis","enrollment":490},{"nctId":"NCT00955279","phase":"PHASE2","title":"A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2009-11","conditions":"Sarcoidosis","enrollment":173},{"nctId":"NCT00723528","phase":"PHASE3","title":"An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-03","conditions":"Psoriasis","enrollment":158},{"nctId":"NCT01077362","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-03","conditions":"Arthritis, Psoriatic","enrollment":312},{"nctId":"NCT00265122","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2004-04","conditions":"Crohn Disease","enrollment":131},{"nctId":"NCT00267969","phase":"PHASE3","title":"A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis","status":"COMPLETED","sponsor":"Centocor Research & Development, Inc.","startDate":"2005-12","conditions":"Psoriasis","enrollment":766},{"nctId":"NCT00771667","phase":"PHASE2","title":"A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2008-12","conditions":"Crohn's Disease","enrollment":526},{"nctId":"NCT00307437","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Centocor Research & Development, Inc.","startDate":"2005-05","conditions":"Psoriasis","enrollment":1230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ustekinumab SC","genericName":"Ustekinumab SC","companyName":"Janssen Research & Development, LLC","companyId":"johnson-johnson","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ustekinumab SC is an interleukin-12 inhibitor, a type of antibody that belongs to the drug class of inhibitors. It is used to treat various conditions, including Crohn's disease, ulcerative colitis, moderate to severe plaque psoriasis, and systemic lupus erythematosus, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}